1. Home
  2. NAKA vs CTNM Comparison

NAKA vs CTNM Comparison

Compare NAKA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAKA
  • CTNM
  • Stock Information
  • Founded
  • NAKA 2019
  • CTNM 2009
  • Country
  • NAKA United States
  • CTNM United States
  • Employees
  • NAKA N/A
  • CTNM N/A
  • Industry
  • NAKA
  • CTNM
  • Sector
  • NAKA
  • CTNM
  • Exchange
  • NAKA Nasdaq
  • CTNM Nasdaq
  • Market Cap
  • NAKA 347.4M
  • CTNM 328.1M
  • IPO Year
  • NAKA 2024
  • CTNM 2024
  • Fundamental
  • Price
  • NAKA $0.91
  • CTNM $10.90
  • Analyst Decision
  • NAKA Strong Buy
  • CTNM Strong Buy
  • Analyst Count
  • NAKA 2
  • CTNM 5
  • Target Price
  • NAKA $5.00
  • CTNM $22.20
  • AVG Volume (30 Days)
  • NAKA 34.2M
  • CTNM 93.7K
  • Earning Date
  • NAKA 11-05-2025
  • CTNM 11-06-2025
  • Dividend Yield
  • NAKA N/A
  • CTNM N/A
  • EPS Growth
  • NAKA N/A
  • CTNM N/A
  • EPS
  • NAKA N/A
  • CTNM N/A
  • Revenue
  • NAKA $2,239,936.00
  • CTNM N/A
  • Revenue This Year
  • NAKA N/A
  • CTNM N/A
  • Revenue Next Year
  • NAKA $2,755.19
  • CTNM N/A
  • P/E Ratio
  • NAKA N/A
  • CTNM N/A
  • Revenue Growth
  • NAKA N/A
  • CTNM N/A
  • 52 Week Low
  • NAKA $0.65
  • CTNM $3.35
  • 52 Week High
  • NAKA $34.77
  • CTNM $20.24
  • Technical
  • Relative Strength Index (RSI)
  • NAKA 34.72
  • CTNM 46.91
  • Support Level
  • NAKA $0.84
  • CTNM $10.77
  • Resistance Level
  • NAKA $0.79
  • CTNM $11.34
  • Average True Range (ATR)
  • NAKA 0.10
  • CTNM 0.66
  • MACD
  • NAKA 0.23
  • CTNM -0.17
  • Stochastic Oscillator
  • NAKA 61.52
  • CTNM 27.31

About NAKA Kindly MD Inc. Common Stock

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: